JP2024506647A - Ccr4ターゲティングキメラ抗原受容体細胞療法 - Google Patents

Ccr4ターゲティングキメラ抗原受容体細胞療法 Download PDF

Info

Publication number
JP2024506647A
JP2024506647A JP2023548583A JP2023548583A JP2024506647A JP 2024506647 A JP2024506647 A JP 2024506647A JP 2023548583 A JP2023548583 A JP 2023548583A JP 2023548583 A JP2023548583 A JP 2023548583A JP 2024506647 A JP2024506647 A JP 2024506647A
Authority
JP
Japan
Prior art keywords
cells
ccr4
domain
car
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506647A5 (cg-RX-API-DMAC7.html
Inventor
カール エイチ. ジューン
慶介 渡邊
レジーナ エム. ヤング
ジョン シェラー
博嘉 西川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Centre Japan
Original Assignee
National Cancer Centre Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Centre Japan filed Critical National Cancer Centre Japan
Publication of JP2024506647A publication Critical patent/JP2024506647A/ja
Publication of JP2024506647A5 publication Critical patent/JP2024506647A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4219—Receptors for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2023548583A 2021-02-11 2022-02-10 Ccr4ターゲティングキメラ抗原受容体細胞療法 Pending JP2024506647A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148489P 2021-02-11 2021-02-11
US63/148,489 2021-02-11
PCT/US2022/015981 WO2022173950A1 (en) 2021-02-11 2022-02-10 Ccr4-targeting chimeric antigen receptor cell therapy

Publications (2)

Publication Number Publication Date
JP2024506647A true JP2024506647A (ja) 2024-02-14
JP2024506647A5 JP2024506647A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=82837290

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548583A Pending JP2024506647A (ja) 2021-02-11 2022-02-10 Ccr4ターゲティングキメラ抗原受容体細胞療法

Country Status (8)

Country Link
US (1) US20240122981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4291207A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506647A (cg-RX-API-DMAC7.html)
KR (1) KR20230171919A (cg-RX-API-DMAC7.html)
CN (1) CN117500838A (cg-RX-API-DMAC7.html)
AU (1) AU2022220694A1 (cg-RX-API-DMAC7.html)
CA (1) CA3207861A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173950A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026160421A1 (ja) * 2025-01-23 2026-07-30 国立研究開発法人国立がん研究センター エフェクターt細胞、およびそれを含む医薬組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
JP2018504894A (ja) * 2014-12-19 2018-02-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体およびその使用方法
JP2019536469A (ja) * 2016-09-21 2019-12-19 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
WO2020132327A1 (en) * 2018-12-19 2020-06-25 The Trustees Of The University Of Pennsylvania Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
WO2020181164A1 (en) * 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
WO2020183131A1 (en) * 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2020239005A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 靶向Claudin18.2的抗体或嵌合抗原受体
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013627A1 (ja) * 2005-07-28 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. Bリンパ腫およびホジキンリンパ腫の治療剤
EP2476438B1 (en) * 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015513394A (ja) * 2012-02-13 2015-05-14 シアトル チルドレンズ ホスピタル ドゥーイング ビジネ 二重特異性キメラ抗原受容体およびその治療的使用
JP2018504894A (ja) * 2014-12-19 2018-02-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド キメラ抗原受容体およびその使用方法
JP2019536469A (ja) * 2016-09-21 2019-12-19 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ ケモカイン受容体ccr4を標的にするキメラ抗原受容体(car)およびその使用
WO2020132327A1 (en) * 2018-12-19 2020-06-25 The Trustees Of The University Of Pennsylvania Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
WO2020181164A1 (en) * 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
WO2020183131A1 (en) * 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
WO2020239005A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 靶向Claudin18.2的抗体或嵌合抗原受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PERERA, L.P., ET AL.: ""Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic mod", AM. J. HEMATOL., vol. 92, no. 9, JPN6026001135, September 2017 (2017-09-01), pages 892 - 901, ISSN: 0005772369 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026160421A1 (ja) * 2025-01-23 2026-07-30 国立研究開発法人国立がん研究センター エフェクターt細胞、およびそれを含む医薬組成物

Also Published As

Publication number Publication date
AU2022220694A1 (en) 2023-08-10
EP4291207A1 (en) 2023-12-20
US20240122981A1 (en) 2024-04-18
CN117500838A (zh) 2024-02-02
EP4291207A4 (en) 2025-02-19
CA3207861A1 (en) 2022-08-18
AU2022220694A9 (en) 2024-07-25
KR20230171919A (ko) 2023-12-21
WO2022173950A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7621344B2 (ja) 線維芽細胞活性化タンパク質(fap)を標的とすることによる腫瘍組織の破壊の方法
JP7748935B2 (ja) IL13Rα2陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成CAR
US20230085834A1 (en) Chimeric Antigen Receptors Comprising Interleukin-9 Receptor Signaling Domain
US20220380447A1 (en) Fibronectin targeting chimeric antigen receptors (cars)
JP2024509917A (ja) 腫瘍溶解性ウイルスによる直交性il-2の送達を用いた、固形腫瘍におけるt細胞の選択的刺激方法
US20240335539A1 (en) Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy
US20250177442A1 (en) Boosting chimeric antigen receptor cells in the blood
US20240122981A1 (en) CCR4-Targeting Chimeric Antigen Receptor Cell Therapy
CN118339178A (zh) 包括白细胞介素-9受体信号传导结构域的嵌合抗原受体
US20240374641A1 (en) Generation of car modifiers for tumor treatment
HK40108209A (en) Ccr4-targeting chimeric antigen receptor cell therapy
HK40127569A (en) Generation of car modifiers for tumor treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260707

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260714

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260806